image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 3.34
-8.45 %
$ 1.88 M
Market Cap
-0.06
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NDRA stock under the worst case scenario is HIDDEN Compared to the current market price of 3.34 USD, ENDRA Life Sciences Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NDRA stock under the base case scenario is HIDDEN Compared to the current market price of 3.34 USD, ENDRA Life Sciences Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one NDRA stock under the best case scenario is HIDDEN Compared to the current market price of 3.34 USD, ENDRA Life Sciences Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NDRA

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-11.5 M NET INCOME
-14.39%
-7.4 M OPERATING CASH FLOW
22.50%
-12.8 K INVESTING CASH FLOW
48.24%
7.81 M FINANCING CASH FLOW
3.87%
0 REVENUE
0.00%
-4.3 M OPERATING INCOME
-184.74%
-4.15 M NET INCOME
-76.25%
-1.52 M OPERATING CASH FLOW
8.54%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet ENDRA Life Sciences Inc.
image
Current Assets 3.43 M
Cash & Short-Term Investments 3.23 M
Receivables 0
Other Current Assets 204 K
Non-Current Assets 1.02 M
Long-Term Investments 0
PP&E 647 K
Other Non-Current Assets 371 K
72.53 %4.59 %14.54 %8.34 %Total Assets$4.5m
Current Liabilities 605 K
Accounts Payable 270 K
Short-Term Debt 96.9 K
Other Current Liabilities 239 K
Non-Current Liabilities 1.29 M
Long-Term Debt 487 K
Other Non-Current Liabilities 799 K
14.25 %5.12 %12.61 %25.77 %42.25 %Total Liabilities$1.9m
EFFICIENCY
Earnings Waterfall ENDRA Life Sciences Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 10.8 M
Operating Income 0
Other Expenses 11.5 M
Net Income -11.5 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)000(11m)0(12m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-449.46% ROE
-449.46%
-258.47% ROA
-258.47%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ENDRA Life Sciences Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.5 M
Depreciation & Amortization 206 K
Capital Expenditures -16 K
Stock-Based Compensation 572 K
Change in Working Capital 134 K
Others 3.09 M
Free Cash Flow -7.42 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ENDRA Life Sciences Inc.
image
NDRA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership ENDRA Life Sciences Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
2.05 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Comp. businesswire.com - 1 month ago
What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock ENDRA Life Sciences (NDRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listi. businesswire.com - 5 months ago
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its conti. businesswire.com - 5 months ago
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.” The ‘282 patent relates to a novel method and system for monitoring tissue ablation during minimally invasive thermal surgical interventions by utilizing ENDRA's TAEUS® system. It is related to ENDRA. businesswire.com - 5 months ago
Data I/O And 2 Other Stocks Under $5 Executives Are Buying The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. benzinga.com - 8 months ago
ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. seekingalpha.com - 8 months ago
ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14 ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate develop. businesswire.com - 8 months ago
Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today? ENDRA Life Sciences (NASDAQ: NDRA ) stock is up on Monday after the clinical diagnostic ultrasound technology company revealed an investment from S.H.N. Financial Investments Ltd. investorplace.com - 10 months ago
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is. businesswire.com - 10 months ago
AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best will host a complimentary webinar titled “The Case for Engaging Defense Counsel Pre-Lawsuit,” on June 25, 2024, at 2:00 p.m. ET. In this webinar, sponsored by Three Griffins, Inc., a panel of insurance claims experts will examine the path from claim to lawsuit, and best practices on minimizing loss through appropriate legal consultation. Register now. Panelists include: Daniel Herbert, president/CEO, Three Griffins, Inc. Donald J. Richardson, shareholder,. businesswire.com - 10 months ago
ENDRA Provides Update Following In-person Meeting with FDA ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing. Prior to the meeting, ENDRA provided the FDA with a detailed description of the TAEUS technology to be used in cl. businesswire.com - 11 months ago
8. Profile Summary

ENDRA Life Sciences Inc. NDRA

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 1.88 M
Dividend Yield 0.00%
Description ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Contact 3600 Green Court, Ann Arbor, MI, 48105-1570 https://www.endrainc.com
IPO Date June 30, 2017
Employees 21
Officers Mr. Michael Thornton Ph.D. Chief Technology Officer Mr. Steve Freeman Human Resources Leader Mr. Ziad Rouag Head of Regulatory & Clinical Affairs Mr. Alexander Y. Tokman Acting Chief Executive Officer & Chairman Mr. Richard Jacroux Chief Financial Officer & Secretary Dr. Jonathan Behr Ph.D. Co-Founder